A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

Immunisation with nirsevimab reduced bronchiolitis-related hospitalisations among infants younger than 3 months who visited the emergency department (ED), according to a new study. Nirsevimab also ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.It will mean all newborn ...

Sanofi joins force with Samitivej International Children’s Hospital to launch the “Together Against RSV” awareness campaign in Thailand, with the support from the Pediatric Infectious Disease Society ...